发布求助
文献互助 智能选刊 最新文献

Im Fokus Onkologie最新文献

筛选
英文 中文
Die meisten Patienten mit Krebsdiagnose trinken Alkohol 大多数确诊癌症的患者都饮酒
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3710-4
Robert Bublak
{"title":"Die meisten Patienten mit Krebsdiagnose trinken Alkohol","authors":"Robert Bublak","doi":"10.1007/s15015-023-3710-4","DOIUrl":"https://doi.org/10.1007/s15015-023-3710-4","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139686432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmazeutische Betreuung in der Onkologie 肿瘤药物治疗
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3739-z
K. Bornemann
{"title":"Pharmazeutische Betreuung in der Onkologie","authors":"K. Bornemann","doi":"10.1007/s15015-024-3739-z","DOIUrl":"https://doi.org/10.1007/s15015-024-3739-z","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PD-1-Hemmer verlängert Leben bei Nasopharynxkarzinom PD-1抑制剂可延长鼻咽癌患者的寿命
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3753-1
T. Müller
{"title":"PD-1-Hemmer verlängert Leben bei Nasopharynxkarzinom","authors":"T. Müller","doi":"10.1007/s15015-024-3753-1","DOIUrl":"https://doi.org/10.1007/s15015-024-3753-1","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mammakarzinom: Lebensqualität bleibt unter T-DXd erhalten 乳腺癌：使用 T-DXd 可保持生活质量
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3702-4
J. Neumaier
{"title":"Mammakarzinom: Lebensqualität bleibt unter T-DXd erhalten","authors":"J. Neumaier","doi":"10.1007/s15015-023-3702-4","DOIUrl":"https://doi.org/10.1007/s15015-023-3702-4","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139685104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ovarial-Ca.: PARP-Hemmer auch bei R0-Resektion vorteilhaft 卵巢癌：PARP 抑制剂也有利于 R0 切除术
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3720-2
T. Müller
{"title":"Ovarial-Ca.: PARP-Hemmer auch bei R0-Resektion vorteilhaft","authors":"T. Müller","doi":"10.1007/s15015-023-3720-2","DOIUrl":"https://doi.org/10.1007/s15015-023-3720-2","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139686379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibitoren von Histondeacetylasen 组织乙酰抑制剂
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3737-1
Sabrina Kempe
{"title":"Inhibitoren von Histondeacetylasen","authors":"Sabrina Kempe","doi":"10.1007/s15015-024-3737-1","DOIUrl":"https://doi.org/10.1007/s15015-024-3737-1","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139686401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Früher Brustkrebs: Deeskalierte Chemotherapie im Vorteil 早期乳腺癌：降级化疗具有优势
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3721-1
T. Müller
{"title":"Früher Brustkrebs: Deeskalierte Chemotherapie im Vorteil","authors":"T. Müller","doi":"10.1007/s15015-023-3721-1","DOIUrl":"https://doi.org/10.1007/s15015-023-3721-1","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
UGN-101 beim Urothelkarzinom retrograd oder antegrad instillieren? UGN-101 在尿路上皮癌中是逆行灌注还是前行灌注？
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3728-2
N. Zink
{"title":"UGN-101 beim Urothelkarzinom retrograd oder antegrad instillieren?","authors":"N. Zink","doi":"10.1007/s15015-024-3728-2","DOIUrl":"https://doi.org/10.1007/s15015-024-3728-2","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140466106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wann aus dem Barrett-Ösophagus ein Adenokarzinom wird 当巴雷特食道变为腺癌时
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3706-0
T. Müller
{"title":"Wann aus dem Barrett-Ösophagus ein Adenokarzinom wird","authors":"T. Müller","doi":"10.1007/s15015-023-3706-0","DOIUrl":"https://doi.org/10.1007/s15015-023-3706-0","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139684642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCC: PD1-Hemmer Tislelizumab bewährt sich in der Erstlinie HCC：PD1抑制剂tislelizumab证明了其在一线治疗中的价值
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3716-y
T. Müller
{"title":"HCC: PD1-Hemmer Tislelizumab bewährt sich in der Erstlinie","authors":"T. Müller","doi":"10.1007/s15015-023-3716-y","DOIUrl":"https://doi.org/10.1007/s15015-023-3716-y","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139684767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信